tiprankstipranks
Genmab A/S (GMAB)
NASDAQ:GMAB
US Market
GMAB
Genmab
RESEARCH TOOLSreports
Want to see GMAB full AI Analyst Report?

Genmab (GMAB) Stock Forecast & Price Target

776 Followers
See the Price Targets and Ratings of:

GMAB Analyst Ratings

Strong Buy
10Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Genmab
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GMAB Stock 12 Month Forecast

Average Price Target

$37.56
▲(31.54% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Genmab in the last 3 months. The average price target is $37.56 with a high forecast of $48.00 and a low forecast of $30.50. The average price target represents a 31.54% change from the last price of $28.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","25":"$25","33":"$33","41":"$41","49":"$49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.55555555555556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,25,33,41,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.22,28.818461538461538,30.416923076923077,32.01538461538461,33.613846153846154,35.21230769230769,36.81076923076923,38.40923076923077,40.00769230769231,41.606153846153845,43.20461538461539,44.80307692307692,46.401538461538465,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.22,28.015042735042734,28.81008547008547,29.605128205128203,30.40017094017094,31.195213675213676,31.99025641025641,32.78529914529915,33.580341880341884,34.37538461538462,35.17042735042735,35.96547008547009,36.76051282051282,{"y":37.55555555555556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.22,27.47230769230769,27.724615384615383,27.976923076923075,28.229230769230767,28.48153846153846,28.73384615384615,28.986153846153847,29.23846153846154,29.49076923076923,29.743076923076924,29.995384615384616,30.247692307692308,{"y":30.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.77,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.61,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.65,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$48.00Average Price Target$37.56Lowest Price Target$30.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GMAB
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
04/27/26
Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
Goldman Sachs Analyst forecast on GMAB
Rajan Sharma
Goldman Sachs
Goldman Sachs
$30.5
Buy
6.83%
Upside
Upgraded
04/22/26
Genmab upgraded to Buy from Neutral at Goldman SachsGenmab upgraded to Buy from Neutral at Goldman Sachs
Wells Fargo Analyst forecast on GMAB
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$40
Buy
40.11%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Stryker (NYSE: SYK) and Genmab (NASDAQ: GMAB)
TD Cowen Analyst forecast on GMAB
Yaron Werber
TD Cowen
TD Cowen
$32
Hold
12.08%
Upside
Reiterated
04/13/26
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
Wolfe Research Analyst forecast on GMAB
Kalpit Patel
Wolfe Research
Wolfe Research
$32
Buy
12.08%
Upside
Initiated
03/26/26
Genmab initiated with an Outperform at Wolfe ResearchGenmab initiated with an Outperform at Wolfe Research
Truist Financial Analyst forecast on GMAB
Asthika Goonewardene
Truist Financial
Truist Financial
$48
Buy
68.13%
Upside
Reiterated
02/25/26
Truist Financial Sticks to Their Buy Rating for Genmab (GMAB)
Guggenheim Analyst forecast on GMAB
Michael Schmidt
Guggenheim
Guggenheim
$45→$40
Buy
40.11%
Upside
Reiterated
02/23/26
Genmab price target lowered to $40 from $45 at GuggenheimGenmab price target lowered to $40 from $45 at Guggenheim
H.C. Wainwright Analyst forecast on GMAB
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$39→$40
Buy
40.11%
Upside
Reiterated
02/18/26
Genmab price target raised to $40 from $39 at H.C. WainwrightGenmab price target raised to $40 from $39 at H.C. Wainwright
Morgan Stanley Analyst forecast on GMAB
Judah Frommer
Morgan Stanley
Morgan Stanley
$34
Hold
19.09%
Upside
Reiterated
02/18/26
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
Jefferies Analyst forecast on GMAB
Benjamin Jackson CFA
Jefferies
Jefferies
$41.5
Buy
45.36%
Upside
Initiated
02/17/26
Genmab resumed with a Buy at JefferiesGenmab resumed with a Buy at Jefferies
Bank of America Securities Analyst forecast on GMAB
Charlie Haywood
Bank of America Securities
Bank of America Securities
$34.7→$38.5
Buy
34.85%
Upside
Reiterated
01/19/26
Genmab price target raised to $38.50 from $34.70 at BofAGenmab price target raised to $38.50 from $34.70 at BofA
Leerink Partners Analyst forecast on GMAB
Jonathan Chang
Leerink Partners
Leerink Partners
$34→$39
Buy
36.60%
Upside
Reiterated
10/13/25
Leerink Partners Reaffirms Their Buy Rating on Genmab (GMAB)
Bernstein Analyst forecast on GMAB
Justin Smith
Bernstein
Bernstein
―
Sell
―
Reiterated
09/08/25
Bernstein Remains a Sell on Genmab (GMAB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GMAB
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
04/27/26
Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
Goldman Sachs Analyst forecast on GMAB
Rajan Sharma
Goldman Sachs
Goldman Sachs
$30.5
Buy
6.83%
Upside
Upgraded
04/22/26
Genmab upgraded to Buy from Neutral at Goldman SachsGenmab upgraded to Buy from Neutral at Goldman Sachs
Wells Fargo Analyst forecast on GMAB
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$40
Buy
40.11%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Stryker (NYSE: SYK) and Genmab (NASDAQ: GMAB)
TD Cowen Analyst forecast on GMAB
Yaron Werber
TD Cowen
TD Cowen
$32
Hold
12.08%
Upside
Reiterated
04/13/26
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
Wolfe Research Analyst forecast on GMAB
Kalpit Patel
Wolfe Research
Wolfe Research
$32
Buy
12.08%
Upside
Initiated
03/26/26
Genmab initiated with an Outperform at Wolfe ResearchGenmab initiated with an Outperform at Wolfe Research
Truist Financial Analyst forecast on GMAB
Asthika Goonewardene
Truist Financial
Truist Financial
$48
Buy
68.13%
Upside
Reiterated
02/25/26
Truist Financial Sticks to Their Buy Rating for Genmab (GMAB)
Guggenheim Analyst forecast on GMAB
Michael Schmidt
Guggenheim
Guggenheim
$45→$40
Buy
40.11%
Upside
Reiterated
02/23/26
Genmab price target lowered to $40 from $45 at GuggenheimGenmab price target lowered to $40 from $45 at Guggenheim
H.C. Wainwright Analyst forecast on GMAB
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$39→$40
Buy
40.11%
Upside
Reiterated
02/18/26
Genmab price target raised to $40 from $39 at H.C. WainwrightGenmab price target raised to $40 from $39 at H.C. Wainwright
Morgan Stanley Analyst forecast on GMAB
Judah Frommer
Morgan Stanley
Morgan Stanley
$34
Hold
19.09%
Upside
Reiterated
02/18/26
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
Jefferies Analyst forecast on GMAB
Benjamin Jackson CFA
Jefferies
Jefferies
$41.5
Buy
45.36%
Upside
Initiated
02/17/26
Genmab resumed with a Buy at JefferiesGenmab resumed with a Buy at Jefferies
Bank of America Securities Analyst forecast on GMAB
Charlie Haywood
Bank of America Securities
Bank of America Securities
$34.7→$38.5
Buy
34.85%
Upside
Reiterated
01/19/26
Genmab price target raised to $38.50 from $34.70 at BofAGenmab price target raised to $38.50 from $34.70 at BofA
Leerink Partners Analyst forecast on GMAB
Jonathan Chang
Leerink Partners
Leerink Partners
$34→$39
Buy
36.60%
Upside
Reiterated
10/13/25
Leerink Partners Reaffirms Their Buy Rating on Genmab (GMAB)
Bernstein Analyst forecast on GMAB
Justin Smith
Bernstein
Bernstein
―
Sell
―
Reiterated
09/08/25
Bernstein Remains a Sell on Genmab (GMAB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genmab

3 Months
xxx
Success Rate
5/7 ratings generated profit
71%
Average Return
+8.89%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +8.89% per trade.
1 Year
Jonathan ChangLeerink Partners
Success Rate
6/7 ratings generated profit
86%
Average Return
+24.34%
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +24.34% per trade.
2 Years
xxx
Success Rate
6/7 ratings generated profit
86%
Average Return
+21.37%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +21.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GMAB Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
5
4
2
1
1
Buy
21
16
15
13
10
Hold
2
2
3
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
22
20
16
14
In the current month, GMAB has received 11 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. GMAB average Analyst price target in the past 3 months is 37.56.
Each month's total comprises the sum of three months' worth of ratings.

GMAB Financial Forecast

GMAB Earnings Forecast

Next quarter’s earnings estimate for GMAB is $0.16 with a range of $0.05 to $0.31. The previous quarter’s EPS was $0.05. GMAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GMAB has Performed in-line its overall industry.
Next quarter’s earnings estimate for GMAB is $0.16 with a range of $0.05 to $0.31. The previous quarter’s EPS was $0.05. GMAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GMAB has Performed in-line its overall industry.

GMAB Sales Forecast

Next quarter’s sales forecast for GMAB is $905.88M with a range of $820.00M to $1.02B. The previous quarter’s sales results were $1.06B. GMAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GMAB has Performed in-line its overall industry.
Next quarter’s sales forecast for GMAB is $905.88M with a range of $820.00M to $1.02B. The previous quarter’s sales results were $1.06B. GMAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GMAB has Performed in-line its overall industry.

GMAB Stock Forecast FAQ

What is GMAB’s average 12-month price target, according to analysts?
Based on analyst ratings, Genmab A/S’s 12-month average price target is 37.56.
    What is GMAB’s upside potential, based on the analysts’ average price target?
    Genmab A/S has 31.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GMAB a Buy, Sell or Hold?
          Genmab A/S has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Genmab A/S’s price target?
            The average price target for Genmab A/S is 37.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $48.00 ,the lowest forecast is $30.50. The average price target represents 31.54% Increase from the current price of $28.55.
              What do analysts say about Genmab A/S?
              Genmab A/S’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of GMAB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.